ROMA index combined with tumor biomarkers in diagnose of patients with ovarian cancer

Abstract

Objective To analyze the value of the serum HE4 and CA125 and ROMA index in the diagnose of patients with ovarian cancer. Methods The clinical data of 102 patients with pelvic tumor treated at our hospital from February, 2015 to December, 2017 was retrospectively analyzed, including 49 cases of ovarian cancer (observation group 1) and 53 cases of benign tumor (observation group2). 50 healthy persons who received health check-up were chosen at the same time from our hospital as a control group. The serum HE4 and CA125 and ROMA in the three groups were compared. The diagnose values of the HE4, CA125, and ROMA in the patients with ovarian cancer were analyzed. The values of the HE4, CA125, and ROMA in different stages of the patients with ovarian cancer were compared. Results The serum levels of HE4 and CA125 and ROMA were (242.3±123.7) pmol/L, (288.1±146.7) U/ml, and (80.6±15.4)% in the observation group 1, which were obviously higher than those in the observation group 2 and those in the control group (all P<0.05). The sensibility of the combined detection of the HE4, CA125, and ROMA in the patients with ovarian cancer was the highest (88.7%), and AUC was the highest (0.957). The positive rates of HE4, CA125, and ROMA increased as the clinical stages. The CA125 positive rates in different stages had statistical differences (P<0.05). Conclusion The combined detection of HE4, CA125, and ROMA is helpful for early diagnosing patients with ovarian cancer, which has obvious diagnositc value. Key words: Human epididymisprotein4 (HE4); Cancer antigen 125 (CA125); ROMA; Ovarian cancer; Diagnosis